Sophie Chandauka once presented Nandi Life Sciences as a bold leap into biotech. Launched in 2023 with her brother, the firm promised groundbreaking therapies for rare diseases. Today, the company’s website no longer loads, and its digital footprint is rapidly eroding.

The silence around Nandi comes at a pivotal moment. Chandauka now faces scrutiny not just for her startup, but also for her role as chair of Sentebale, a charity co-founded by Prince Harry and currently under regulatory review by the UK’s Charity Commission. As questions over financial decisions mount, the disappearance of Nandi’s online presence adds a new dimension to an unfolding controversy.

Big Promises Without a Public Record

Chandauka described Nandi Life Sciences as a platform for scientific innovation focused on cancer and autoimmune disorders. The company claimed to champion global equity and impact. But there is no evidence of medical staff, published research, or clinical trials. No patents have been filed. Regulatory records show no sign of scientific output or operational momentum.

Meanwhile, Nandi’s visibility continues to shrink. Former staff updated their LinkedIn bios. Some deleted social media. Chandauka has positioned the company as part of a $50 million biotech portfolio, yet no independent source has corroborated the figure or the scope of the venture.

Compounding doubts is the company’s listed address: 2450 Holcombe Blvd, Suite X, Houston—identical to that of TMC Innovation, a respected research institute. Yet there is no record of a formal partnership. The shared location suggests the affiliation may have served optics more than function.

Side-by-side screenshots showing Nandi Life Sciences and TMC Innovation both registered at 2450 Holcombe Blvd, Suite X, Houston, Texas.
Nandi Life Sciences and TMC Innovation list the same Houston address, raising questions about Nandi’s legitimacy and affiliations, as there is no public record of a formal partnership between the two entities.

Related | Sophie Chandauka’s Sentebale Financial Claims Debunked

Consultants, Conflicts, and Charity Money

One name links Nandi and Sentebale directly: Sarah Essien. She worked with Chandauka at Morgan Stanley and served as a consultant at both Nandi and Sentebale. Media-reported records show Sentebale paid her over £41,000 between 2023 and 2024. In total, the charity spent nearly half a million pounds on consultants during that period, many of whom have long-standing ties to Chandauka.

This includes her brother, who co-founded Nandi and reportedly received payments from the charity. If funds flowed—directly or indirectly—from Sentebale to an entity co-chaired by its board leader, that convergence of roles could trigger serious governance issues and legal consequences.

Embed from Getty Images
Dr. Sophie Chandauka and Alix Lebec at a 2024 Sentebale event in Lesotho. Sentebale paid £185,000 to LEBEC, which deleted its Instagram after the board resigned.

Related | Dr Margaret Ikpoh Quits Sentebale After Just Six Days

Charity Commission Investigates While Nandi Disappears

The UK’s Charity Commission has opened a regulatory case to assess whether Sentebale’s board followed its legal and ethical duties. While not yet a full inquiry, the review will examine how decisions were made, including financial transactions and leadership appointments.

Chandauka has denied any wrongdoing and says she welcomes the investigation. Prince Harry, along with Prince Seeiso and five trustees, resigned from Sentebale in March 2025, all citing a breakdown in trust and calling for greater transparency.

Yet the timing of Nandi Life Sciences’ quiet erasure—amid an active investigation—casts a long shadow over its founding claims and Sophie Chandauka’s leadership. A company once framed as visionary now offers no evidence of biotech activity. And Sentebale, founded to support children in Southern Africa, faces the risk of seeing its mission eclipsed by reputational fallout.


Discover more from Feminegra

Subscribe to get the latest posts sent to your email.